Home Healthcare Healthcare Services Cancer Immunotherapy Drug Discovery Outsourcing Market

Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Service Type (Target Identification and Validation, Lead Screening and Characterization, Cell-based Assays), By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Head and Neck, Ovarian, Pancreatic, Othe Types), By Drug Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy, Other Drug Types) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: April 21, 2026 | Author: Debashree B | Format: | Report Code: SR2676DR | Pages: 150
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Cancer Immunotherapy Drug Discovery Outsourcing Market, By Service Type 2022-2034 (USD MILLION/ Units)
    1. Target Identification and Validation
    2. Lead Screening and Characterization
    3. Cell-based Assays
  2. Cancer Immunotherapy Drug Discovery Outsourcing Market, By Cancer Type 2022-2034 (USD MILLION/ Units)
    1. Lung
    2. Breast
    3. Colorectal
    4. Melanoma
    5. Prostate
    6. Head and Neck
    7. Ovarian
    8. Pancreatic
    9. Othe Types
  3. Cancer Immunotherapy Drug Discovery Outsourcing Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Monoclonal Antibodies
    2. Immunomodulators
    3. Cancer Vaccines and Oncolytic Viral Therapy
    4. Other Drug Types
  4. Regional Cancer Immunotherapy Drug Discovery Outsourcing Market
    1. North America
      1. North America Cancer Immunotherapy Drug Discovery Outsourcing Market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
      2. North America Cancer Immunotherapy Drug Discovery Outsourcing Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Lung
        2. Breast
        3. Colorectal
        4. Melanoma
        5. Prostate
        6. Head and Neck
        7. Ovarian
        8. Pancreatic
        9. Othe Types
      3. North America Cancer Immunotherapy Drug Discovery Outsourcing Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Immunomodulators
        3. Cancer Vaccines and Oncolytic Viral Therapy
        4. Other Drug Types
      4. U.S.
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      5. Canada
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
    2. Europe
      1. Europe Cancer Immunotherapy Drug Discovery Outsourcing Market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
      2. Europe Cancer Immunotherapy Drug Discovery Outsourcing Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Lung
        2. Breast
        3. Colorectal
        4. Melanoma
        5. Prostate
        6. Head and Neck
        7. Ovarian
        8. Pancreatic
        9. Othe Types
      3. Europe Cancer Immunotherapy Drug Discovery Outsourcing Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Immunomodulators
        3. Cancer Vaccines and Oncolytic Viral Therapy
        4. Other Drug Types
      4. U.K.
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      5. Germany
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      6. France
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      7. Spain
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      8. Italy
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      9. Russia
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      10. Nordic
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      11. Benelux
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      12. Rest of Europe
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
    3. APAC
      1. APAC Cancer Immunotherapy Drug Discovery Outsourcing Market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
      2. APAC Cancer Immunotherapy Drug Discovery Outsourcing Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Lung
        2. Breast
        3. Colorectal
        4. Melanoma
        5. Prostate
        6. Head and Neck
        7. Ovarian
        8. Pancreatic
        9. Othe Types
      3. APAC Cancer Immunotherapy Drug Discovery Outsourcing Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Immunomodulators
        3. Cancer Vaccines and Oncolytic Viral Therapy
        4. Other Drug Types
      4. China
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      5. Korea
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      6. Japan
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      7. India
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      8. Australia
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      9. Taiwan
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      10. South East Asia
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      11. Rest of Asia-Pacific
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
    4. Middle East and Africa
      1. Middle East and Africa Cancer Immunotherapy Drug Discovery Outsourcing Market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
      2. Middle East and Africa Cancer Immunotherapy Drug Discovery Outsourcing Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Lung
        2. Breast
        3. Colorectal
        4. Melanoma
        5. Prostate
        6. Head and Neck
        7. Ovarian
        8. Pancreatic
        9. Othe Types
      3. Middle East and Africa Cancer Immunotherapy Drug Discovery Outsourcing Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Immunomodulators
        3. Cancer Vaccines and Oncolytic Viral Therapy
        4. Other Drug Types
      4. UAE
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      5. Turkey
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      6. Saudi Arabia
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      7. South Africa
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      8. Egypt
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      9. Nigeria
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      10. Rest of MEA
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
    5. LATAM
      1. LATAM Cancer Immunotherapy Drug Discovery Outsourcing Market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
      2. LATAM Cancer Immunotherapy Drug Discovery Outsourcing Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Lung
        2. Breast
        3. Colorectal
        4. Melanoma
        5. Prostate
        6. Head and Neck
        7. Ovarian
        8. Pancreatic
        9. Othe Types
      3. LATAM Cancer Immunotherapy Drug Discovery Outsourcing Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Monoclonal Antibodies
        2. Immunomodulators
        3. Cancer Vaccines and Oncolytic Viral Therapy
        4. Other Drug Types
      4. Brazil
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      5. Mexico
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      6. Argentina
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      7. Chile
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      8. Colombia
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
      9. Rest of LATAM
        1. Target Identification and Validation
        2. Lead Screening and Characterization
        3. Cell-based Assays
        4. Lung
        5. Breast
        6. Colorectal
        7. Melanoma
        8. Prostate
        9. Head and Neck
        10. Ovarian
        11. Pancreatic
        12. Othe Types
        13. Monoclonal Antibodies
        14. Immunomodulators
        15. Cancer Vaccines and Oncolytic Viral Therapy
        16. Other Drug Types
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.